DermaSensor Postmarket Surveillance Study

NARecruitingINTERVENTIONAL
Enrollment

396

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

April 11, 2027

Study Completion Date

September 10, 2027

Conditions
Melanoma, Skin
Interventions
DEVICE

Scan with elastic scattering spectroscopy device to assess risk of malignancy

Elastic scattering spectroscopy device uses a spectrum of light reflectance to compare suspicious lesion signature to that of previously scanned lesions with known benign or malignant pathology

Trial Locations (2)

28557

RECRUITING

West Clinical Research, Morehead City

32168

RECRUITING

Velocity, New Smyrna Beach

Sponsors

Lead Sponsor

All Listed Sponsors
lead

DermaSensor, Inc.

INDUSTRY

NCT06666790 - DermaSensor Postmarket Surveillance Study | Biotech Hunter | Biotech Hunter